FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences was founded in 2009 by Sopartec SA, the technology transfer company for the Université Catholique de Louvain and Professor Etienne Sokal, a leading expert in hepatology and cell therapy. In May 2009, Eric Halioua became the Chief Executive Officer of Promethera® Biosciences.
End of October 2009, Promethera® Biosciences has completed a 5.3 million euros A-round of funding.
Promethera® biosciences’ technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: human Adult Liver-Derived Mesenchymal progenitor/Stem cell (hALDMSC). Promethera® biosciences has developed an innovative technology to isolate and expand the progenitor cell type in order to develop two products: Promethera® HepaStem and Promethera® HepaScreen.
Promethera® Biosciences has signed several research and collaborative agreements with industrial or academic partners:
Promethera® Biosciences also received funding from: